FIELD: medicine, in particular fluid composition useful as implant with controlled releasing of pharmaceutical agent.
SUBSTANCE: claimed composition contains biodegradable thermoplastic polyester essentially insoluble in aqueous medium or body fluid. Composition also contains biocompatible polar aprotic solvent which is compatible with aqueous medium or body fluid in blendability and dispersability. Fluid composition also contains leuprolide acetate. Method for production of fluid composition also is disclosed. Invention also relates to solid biodegradable implant forming in situ in patient body after injection of fluid composition to patient. Said implant allows dissipation of biocompatible polar aprotic solvent. Invention also relates to kit.
EFFECT: fluid resin compositions for leuprolide delivery of improved effectiveness providing decreased testosterone levels in body.
45 cl, 5 dwg, 7 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS WITH A SELECTED DURATION OF RELEASE | 2017 |
|
RU2756514C1 |
| THIN-FLUID COMPOSITION FOR INJECTIONS CONTAINING BUPRENORPHINE | 2011 |
|
RU2607498C2 |
| COMPOSITIONS AND METHODS FOR LONG-TERM RELEASE OF ANTAGONISTS OF GONADOTROPIN-RELEASING HORMONE (GnRH) | 2018 |
|
RU2789057C2 |
| COMPOSITIONS OF PROLONGEDACTION WITH CONTROLLED RELEASE | 2003 |
|
RU2355385C2 |
| PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY | 2015 |
|
RU2728786C2 |
| INJECTION COMPOSITION CONTAINING GnRH ANALOGUE | 2021 |
|
RU2827376C1 |
| HIGH STABILITY PHARMACEUTICAL COMPOSITIONS | 2007 |
|
RU2427383C2 |
| METHOD OF TREATING PROSTATE CANCER WITH DEGARELIX THAT IS GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST | 2009 |
|
RU2504393C2 |
| LIPID PRECONCENTRATE OF GNRH ANALOGUES WITH DELAYED RELEASE, AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2013 |
|
RU2646487C2 |
| FORMED IN SITU IMPLANT FOR ANIMALS | 2005 |
|
RU2394558C2 |
